Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Lotze

Showing results (191-200 of 242) with videos related to

Pageof 25
Sort By:
The Cancer Journal From Scientific American|February 24, 2000
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunityM T Lotze, M Shurin, C Esche, et al.
The Journal of Clinical Investigation|October 1, 1996
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.
Cancer Research|December 1, 1992
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapyF M Marincola, D Venzon, D White, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1988
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndromeR S Cotran, J S Pober, M A Gimbrone, et al.
Cancer Research|January 1, 1994
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivoH Tahara, H J Zeh, W J Storkus, et al.
The Journal of Clinical Endocrinology and Metabolism|August 1, 1989
The neuroendocrine effects of interleukin-2 treatmentK D Denicoff, T M Durkin, M T Lotze, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|November 1, 1992
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapyJ R Lange, A A Raubitschek, B A Pockaj, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1995
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vectorH Tahara, L Zitvogel, W J Storkus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1986
Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibodyP Perez, J A Titus, M T Lotze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6M J Maeurer, S M Gollin, W J Storkus, et al.
Pageof 25

Showing results (191-200 of 242) with videos related to

Sort By:
Pageof 25
The Cancer Journal From Scientific American|February 24, 2000
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunityM T Lotze, M Shurin, C Esche, et al.
The Journal of Clinical Investigation|October 1, 1996
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.
Cancer Research|December 1, 1992
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapyF M Marincola, D Venzon, D White, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1988
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndromeR S Cotran, J S Pober, M A Gimbrone, et al.
Cancer Research|January 1, 1994
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivoH Tahara, H J Zeh, W J Storkus, et al.
The Journal of Clinical Endocrinology and Metabolism|August 1, 1989
The neuroendocrine effects of interleukin-2 treatmentK D Denicoff, T M Durkin, M T Lotze, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|November 1, 1992
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapyJ R Lange, A A Raubitschek, B A Pockaj, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1995
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vectorH Tahara, L Zitvogel, W J Storkus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1986
Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibodyP Perez, J A Titus, M T Lotze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6M J Maeurer, S M Gollin, W J Storkus, et al.
Pageof 25